Source 1primary paper2026MED
Toolkit/Chimeric antigen receptor (CAR)-based cellular therapy
Chimeric antigen receptor (CAR)-based cellular therapy
Also known as: CAR-based cellular therapy, CAR T-cell therapy
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Chimeric antigen receptor (CAR) T-cell therapy utilizes synthetic biology techniques to engineer T cells to specifically target tumor cells using most commonly single-chain variable fragments (scFvs) to recognize tumor-associated antigens.
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Techniques
No technique tags yet.
Target processes
recombinationValidation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successHuman Clinicaltherapeutic use
Inferred from claim c2 during normalization. CAR T-cell therapy has been successfully applied to patients with B-lineage hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Derived from claim c2.
Source:
mixedHuman Clinicaltherapeutic use
Inferred from claim c6 during normalization. Post-infusion patients may experience severe T-cell aplasia that can worsen immunodeficiency. Derived from claim c6.
Source:
Supporting Sources
Ranked Claims
CAR T-cell therapy has been successfully applied to patients with B-lineage hematologic malignancies including leukemia, lymphoma, and multiple myeloma.
Shared antigens between malignant and normal T cells are a significant challenge because they lead to fratricide among CAR T cells.
Treatment outcomes for relapsed or refractory T-cell malignancies remain suboptimal with CAR-based cellular therapy.
The presence of malignant T cells in patients' leukapheresis may increase the risk of relapse.
CAR T-cell therapy engineers T cells to specifically target tumor cells, most commonly using scFvs to recognize tumor-associated antigens.
CAR-based cellular therapy for T-cell malignancies includes exploration of multiple immune effector cell platforms, including conventional T-cell subsets, NK cells, NKT cells, CIK cells, and γδ T cells.
Post-infusion patients may experience severe T-cell aplasia that can worsen immunodeficiency.
Approval Evidence
1 source7 linked approval claimsfirst-pass slug chimeric-antigen-receptor-car-based-cellular-therapy
Chimeric antigen receptor (CAR) T-cell therapy utilizes synthetic biology techniques to engineer T cells to specifically target tumor cells using most commonly single-chain variable fragments (scFvs) to recognize tumor-associated antigens.
Source:
application statussupports
CAR T-cell therapy has been successfully applied to patients with B-lineage hematologic malignancies including leukemia, lymphoma, and multiple myeloma.
Source:
failure modesupports
Shared antigens between malignant and normal T cells are a significant challenge because they lead to fratricide among CAR T cells.
Source:
limitationsupports
Treatment outcomes for relapsed or refractory T-cell malignancies remain suboptimal with CAR-based cellular therapy.
Source:
manufacturing risksupports
The presence of malignant T cells in patients' leukapheresis may increase the risk of relapse.
Source:
mechanism or designsupports
CAR T-cell therapy engineers T cells to specifically target tumor cells, most commonly using scFvs to recognize tumor-associated antigens.
Source:
scopesupports
CAR-based cellular therapy for T-cell malignancies includes exploration of multiple immune effector cell platforms, including conventional T-cell subsets, NK cells, NKT cells, CIK cells, and γδ T cells.
Source:
toxicity or safetysupports
Post-infusion patients may experience severe T-cell aplasia that can worsen immunodeficiency.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.